Hospital & Healthcare Services · Founded 2010 · www.dragarwals.co.in · BSE 544350 · NSE AGARWALEYE · ISIN INE943P01029
No Notes Added Yet
Business
Dr. Agarwal's Health Care Ltd. is a leading provider of comprehensive ophthalmic (eye care) services. The company operates a chain of eye hospitals, offering a wide range of treatments including cataract surgery, refractive surgery (LASIK, SMILE), retina and glaucoma management, corneal treatments, pediatric ophthalmology, and ocular oncology. Its core business model revolves around providing high-quality, accessible, and technologically advanced eye care services through its network of hospitals. The company generates revenue primarily through consultation fees, surgical procedures, diagnostic services, optical retail, and pharmacy sales.
Revenue Mix
The company's primary business segment is Ophthalmic Healthcare Services. Within this, surgical procedures, particularly cataract surgeries, are significant revenue drivers due to their high volume and procedure value. Other key service lines include retina services, refractive surgeries, glaucoma treatments, and general eye consultations. The company also derives revenue from ancillary services suchibilities like diagnostics, optical retail, and pharmacy. Specific percentage breakdowns for each service line are not publicly provided in the initial company details, but surgical services typically form the largest portion of revenue for such hospital chains.
Industry
Dr. Agarwal's operates in the rapidly growing Indian healthcare sector, specifically the organized ophthalmology segment. The industry is characterized by a mix of large corporate hospital chains, regional multi-specialty hospitals, and numerous standalone clinics. The trend is towards corporatization, with patients increasingly preferring organized players for quality assurance and advanced technology. Dr. Agarwal's is positioned as one of the oldest and largest organized players in Indian ophthalmology, with a strong presence in South India and a growing international footprint (e.g., Africa and parts of Asia). It is known for its clinical expertise, technological adoption, and patient-centric approach, placing it among the top tier of dedicated eye care providers.
MOAT
Dr. Agarwal's possesses several competitive advantages:
Brand Reputation & Trust: A long-standing legacy (founded 1957) has built significant brand equity and patient trust, especially in South India, which is crucial in healthcare.
Clinical Expertise & Technology: A reputation for pioneering surgical techniques and adopting advanced diagnostic and treatment technologies attracts both patients and skilled ophthalmologists.
Scale & Network: A growing pan-India and international network of hospitals provides economies of scale in procurement, marketing, and allows for wider patient reach and referral systems.
Doctor Talent Pool: Ability to attract and retain experienced ophthalmologists and surgeons due to its established brand and infrastructure.
Growth Drivers
Demographic Trends: An aging population in India and globally increases the incidence of age-related eye diseases (e.g., cataracts, glaucoma).
Lifestyle Changes: Increasing screen time and prevalence of chronic diseases like diabetes contribute to rising eye conditions.
Increasing Awareness & Affordability: Growing health awareness and rising disposable incomes are leading to greater demand for quality eye care.
Organized Sector Shift: Patients are increasingly moving from fragmented, unorganized clinics to corporate hospital chains seeking better quality, technology, and standardized care.
Geographic Expansion: Both domestic expansion (into tier 2/3 cities) and international expansion (Africa, Southeast Asia) through greenfield projects and strategic acquisitions.
Medical Tourism: Potential to attract international patients seeking high-quality, cost-effective eye care.
Risks
Intense Competition: Significant competition from other organized eye care chains (e.g., ASG Eye Hospitals, Vasan Eye Care), multi-specialty hospitals, and local players, potentially leading to pricing pressure.
Doctor Dependence & Retention: High reliance on a limited pool of highly skilled ophthalmologists; retaining top talent and recruiting new specialists can be challenging and costly.
Regulatory & Pricing Risks: Potential for government intervention in healthcare pricing (e.g., price caps on procedures, medical devices) which could impact profitability.
Technological Obsolescence: Rapid advancements in ophthalmology require continuous significant capital expenditure for upgrading equipment and adopting new techniques.
Reputational Damage: Any instance of medical negligence, poor patient outcomes, or negative publicity could severely erode patient trust and brand value.
Integration Risks: Challenges associated with integrating new acquisitions (cultural, operational, financial) could dilute efficiency and profitability.
Management & Ownership
Dr. Agarwal's Health Care Ltd. is a promoter-led company with a strong professional management team. It was founded by Dr. J. Agarwal in 1957. The current leadership includes Dr. Amar Agarwal (Chairman) and Dr. Ashvin Agarwal (Managing Director), both acclaimed ophthalmologists. The management combines deep clinical expertise with experience in scaling a large healthcare enterprise. The ownership structure includes significant stakes held by private equity investors (such as Temasek and TPG Growth), indicating institutional backing and a focus on corporate governance and strategic growth.
Outlook
Dr. Agarwal's Health Care is well-positioned to capitalize on the growing demand for quality eye care driven by favorable demographics and increasing health awareness. Its established brand, clinical expertise, and expanding network provide a solid foundation for continued growth, particularly in the organized sector. The company's strategy of both organic and inorganic expansion, including international markets, presents significant growth avenues. However, it faces intense competition, the need for continuous technological investment, and the critical challenge of attracting and retaining highly skilled medical professionals. Regulatory risks and the successful integration of acquired assets will also be key factors in its future performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 333 | 349 | 403 | 417 | 431 | 460 | 487 | 499 | 530 | 564 |
| Other Income | 12 | 20 | 6 | 12 | 13 | 15 | 13 | 8 | 11 | 13 |
| Total Income | 345 | 369 | 409 | 428 | 443 | 476 | 501 | 507 | 540 | 577 |
| Total Expenditure | 244 | 242 | 300 | 310 | 316 | 329 | 360 | 363 | 386 | 403 |
| Operating Profit | 101 | 127 | 110 | 119 | 128 | 146 | 141 | 144 | 155 | 174 |
| Interest | 22 | 27 | 27 | 28 | 28 | 25 | 25 | 23 | 21 | 22 |
| Depreciation | 43 | 46 | 56 | 57 | 58 | 60 | 63 | 68 | 69 | 77 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -3 | 0 | 0 | 0 | 1 |
| Profit Before Tax | 36 | 54 | 27 | 33 | 41 | 59 | 54 | 54 | 65 | 77 |
| Provision for Tax | 13 | 13 | 9 | 12 | 13 | 16 | 16 | 17 | 21 | 27 |
| Profit After Tax | 23 | 41 | 18 | 21 | 28 | 43 | 38 | 36 | 44 | 50 |
| Adjustments | -3 | -3 | -6 | -5 | -6 | -10 | -8 | -7 | -10 | -10 |
| Profit After Adjustments | 20 | 39 | 12 | 17 | 22 | 33 | 30 | 30 | 34 | 40 |
| Adjusted Earnings Per Share | 0.7 | 1.4 | 0 | 0.5 | 0.7 | 1 | 1 | 0.9 | 1.1 | 1.3 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 531 | 471 | 696 | 1018 | 1332 | 1711 | 2080 |
| Other Income | 13 | 14 | 22 | 18 | 49 | 57 | 45 |
| Total Income | 544 | 485 | 718 | 1036 | 1382 | 1768 | 2125 |
| Total Expenditure | 407 | 394 | 514 | 748 | 970 | 1260 | 1512 |
| Operating Profit | 136 | 90 | 203 | 288 | 411 | 509 | 614 |
| Interest | 54 | 44 | 49 | 76 | 101 | 115 | 91 |
| Depreciation | 93 | 95 | 98 | 128 | 170 | 231 | 277 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -3 | 1 |
| Profit Before Tax | -11 | -48 | 57 | 84 | 141 | 160 | 250 |
| Provision for Tax | 9 | 10 | 14 | -20 | 46 | 50 | 81 |
| Profit After Tax | -20 | -58 | 43 | 103 | 95 | 110 | 168 |
| Adjustments | -1 | 3 | -5 | -9 | -12 | -27 | -35 |
| Profit After Adjustments | -21 | -55 | 38 | 94 | 83 | 83 | 134 |
| Adjusted Earnings Per Share | -1 | -2.7 | 1.8 | 4 | 3 | 2.6 | 4.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 28% | 35% | 26% | 0% |
| Operating Profit CAGR | 24% | 36% | 30% | 0% |
| PAT CAGR | 16% | 37% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 30% | NA% | NA% | NA% |
| ROE Average | 7% | 14% | 7% | 5% |
| ROCE Average | 14% | 18% | 15% | 15% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 249 | 184 | 212 | 630 | 1339 | 1867 |
| Minority's Interest | 18 | 14 | 21 | 30 | 40 | 60 |
| Borrowings | 145 | 168 | 254 | 306 | 310 | 157 |
| Other Non-Current Liabilities | 181 | 257 | 318 | 504 | 627 | 1078 |
| Total Current Liabilities | 146 | 150 | 206 | 301 | 400 | 478 |
| Total Liabilities | 740 | 774 | 1012 | 1770 | 2716 | 3640 |
| Fixed Assets | 551 | 575 | 701 | 1293 | 1746 | 2523 |
| Other Non-Current Assets | 44 | 44 | 83 | 167 | 211 | 322 |
| Total Current Assets | 146 | 154 | 227 | 310 | 759 | 794 |
| Total Assets | 740 | 774 | 1012 | 1770 | 2716 | 3640 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 94 | 39 | 55 | 100 | 127 | 112 |
| Cash Flow from Operating Activities | 103 | 99 | 164 | 233 | 346 | 360 |
| Cash Flow from Investing Activities | -80 | -37 | -155 | -509 | -914 | -750 |
| Cash Flow from Financing Activities | -73 | -37 | 35 | 303 | 553 | 382 |
| Net Cash Inflow / Outflow | -50 | 25 | 44 | 27 | -15 | -8 |
| Closing Cash & Cash Equivalent | 39 | 55 | 100 | 127 | 112 | 104 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -1 | -2.7 | 1.83 | 3.96 | 2.97 | 2.64 |
| CEPS(Rs) | 3.57 | 1.77 | 6.84 | 9.74 | 9.48 | 10.8 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 12.1 | 8.95 | 10.32 | 26.4 | 47.63 | 58.77 |
| Core EBITDA Margin(%) | 23.27 | 16.29 | 26.1 | 26.51 | 27.18 | 26.39 |
| EBIT Margin(%) | 8.16 | -0.9 | 15.19 | 15.73 | 18.1 | 16.07 |
| Pre Tax Margin(%) | -2.04 | -10.26 | 8.15 | 8.21 | 10.55 | 9.34 |
| PAT Margin (%) | -3.7 | -12.39 | 6.2 | 10.14 | 7.14 | 6.45 |
| Cash Profit Margin (%) | 13.84 | 7.72 | 20.23 | 22.74 | 19.92 | 19.93 |
| ROA(%) | -2.66 | -7.72 | 4.83 | 7.42 | 4.24 | 3.47 |
| ROE(%) | -7.89 | -26.95 | 21.77 | 24.58 | 9.69 | 6.92 |
| ROCE(%) | 10.53 | -1.09 | 24.26 | 21.51 | 17.77 | 14.32 |
| Receivable days | 36.06 | 38.4 | 27.12 | 23.85 | 23.72 | 23.51 |
| Inventory Days | 22.99 | 23.75 | 15.94 | 12.36 | 12.05 | 14.1 |
| Payable days | 340.04 | 419.56 | 356.83 | 306.23 | 312.42 | 322 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 169.15 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 7.6 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.23 | 0.27 | 0.26 | 0.21 | 0.2 | 8.24 |
| EV/Core EBITDA(x) | 0.91 | 1.4 | 0.89 | 0.75 | 0.66 | 27.73 |
| Net Sales Growth(%) | 0 | -11.23 | 47.73 | 46.25 | 30.86 | 28.44 |
| EBIT Growth(%) | 0 | -109.84 | 2580.75 | 51.37 | 50.61 | 14.07 |
| PAT Growth(%) | 0 | -197.11 | 173.94 | 139.16 | -7.92 | 16.09 |
| EPS Growth(%) | 0 | -170.22 | 167.94 | 116.06 | -25.01 | -10.97 |
| Debt/Equity(x) | 0.65 | 1.01 | 1.37 | 0.57 | 0.29 | 0.13 |
| Current Ratio(x) | 1 | 1.03 | 1.1 | 1.03 | 1.9 | 1.66 |
| Quick Ratio(x) | 0.77 | 0.84 | 0.94 | 0.91 | 1.77 | 1.49 |
| Interest Cover(x) | 0.8 | -0.1 | 2.16 | 2.09 | 2.4 | 2.39 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0.02 |
| # | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 32.45 | 32.42 | 32.42 | 32.39 | 32.36 |
| FII | 40.49 | 39.16 | 38.03 | 37.97 | 37.88 |
| DII | 25.34 | 26.54 | 28.03 | 27.87 | 27.9 |
| Public | 1.72 | 1.88 | 1.52 | 1.77 | 1.87 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 |
| FII | 12.79 | 12.38 | 12.02 | 12.02 | 12 |
| DII | 8 | 8.39 | 8.86 | 8.82 | 8.84 |
| Public | 0.54 | 0.59 | 0.48 | 0.56 | 0.59 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 31.59 | 31.62 | 31.62 | 31.65 | 31.68 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +28% | +35% | +26% | — |
| Operating Profit CAGR | +24% | +36% | +30% | — |
| PAT CAGR | +16% | +37% | — | — |
| Share Price CAGR | +30% | — | — | — |
| ROE Average | +7% | +14% | +7% | +5% |
| ROCE Average | +14% | +18% | +15% | +15% |
| # | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 32.45 | 32.42 | 32.42 | 32.39 | 32.36 |
| FII | 40.49 | 39.16 | 38.03 | 37.97 | 37.88 |
| DII | 25.34 | 26.54 | 28.03 | 27.87 | 27.9 |
| Public | 67.55 | 67.58 | 67.58 | 67.61 | 67.64 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 |
| FII | 12.79 | 12.38 | 12.02 | 12.02 | 12 |
| DII | 8 | 8.39 | 8.86 | 8.82 | 8.84 |
| Public | 21.34 | 21.37 | 21.37 | 21.4 | 21.43 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 31.59 | 31.62 | 31.62 | 31.65 | 31.68 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.